MYC and glioblastoma: Among the pathways we identified in the high-risk genes, MYC targets are attractive because MYC has multiple protumorigenic functions in glioblastoma.40,41 There are currently no clinically viable MYC inhibitors.42 Developing these inhibitors may have utility in treating the most aggressive glioblastomas.